TriangleAtezolizumab (NCT07322341)
Atezolizumab trial for Advanced Lung Non-Small Cell Carcinoma (NCT07322341). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic, recurrent or locally incurable stage IIIC non-small-cell lung cancer, after platinum chemotherapy and progression on checkpoint therapy. EGFR, ALK, ROS1 and RET driver alterations are excluded.
The idea: SX-682 blocks CXCR1/2 signals that attract immune-suppressing cells; atezolizumab blocks PD-L1. Patients take SX-682 twice daily, starting one week before atezolizumab injections every three weeks. Researchers measure tumor response. Actionable alterations require prior targeted treatment. Biopsy is requested if safe.
This phase 2 study plans 32 patients. Christina Baik leads at Fred Hutch/University of Washington’s recruiting Seattle site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.